Track Your Progress

Step 1 Register to track your progress

Step 2 Review content

Step 3 Complete the Knowledge Checkpoints

The correct answer is C.

NSCLC comprises approximately 85% of lung cancer cases, while SCLC comprises approximately 15% of lung cancer cases.

The correct answer is A.

Approximately 1 in 4 cancer deaths are due to lung cancer, which is more than colon, breast, and prostate cancers combined.

The correct answer is B.

The 5-year survival rate for metastatic or stage IV NSCLC is approximately 1%.

The correct answer is B.

A point mutation means that a specific part of the gene is changed, as is the case with L858R mutations.

The correct answer is B.

The incidence of EGFR sensitizing mutations in patients with metastatic NSCLC varies by ethnicity. 7% to 23% of patients with metastatic NSCLC in Western populations contain sensitizing mutations in EGFR.

The correct answer is D.

The most common EGFR sensitizing mutations are exon 19 deletions and L858R point mutations.

The correct answer is A.

The L858R EGFR point mutation is considered a sensitizing mutation.

The correct answer is A.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend testing for all actionable biomarkers at diagnosis of NSCLC, including EGFR, ALK, BRAF, ROS1, and PD-L1 mutations or expression.

Certification

Knowledge Checkpoint 1:

Become a Diagnostic Navigator

Becoming the Diagnostic Navigator in your oncology practice begins here. To test your knowledge, complete this Knowledge Checkpoint. If you have any incorrect answers, review the material again and retest.

You need 5/5 correct answers to pass the test. Good luck!

Quiz 1

Thanks for showing interest in our survey! But this survey requires you to login. Please Click Below